Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced a strategic refocusing of its research and development portfolio, following the expiration and termination of its option and license arrangements with PinCell S.r.l. related to PC111. The decision, effective August 31, was not prompted by any new negative scientific findings regarding PC111, according to the company. Instead, the move is designed to concentrate R&D resources on its proprietary NanoAb platform while preserving capital and management capacity for its contract development and manufacturing organization (CDMO) business.
The company is advancing two IL-17 programs within the NanoAb platform, including an intradermal psoriasis program that is currently under evaluation for approximately €12 million in grant financing in Poland. This potential funding would significantly support the development of this program. In addition, Scinai reported approximately $3.1 million in committed CDMO customer orders as of August 16, with the company continuing to pursue approximately $5 million in CDMO revenue for 2026. These figures are subject to project execution, timing, revenue recognition, and additional business opportunities.
Scinai Immunotherapeutics is a biopharmaceutical company that combines immunology therapeutic development with a revenue-generating CDMO. The company's pipeline includes therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. Scinai also owns Scinai Biopharma Services Ltd., a CDMO that provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.
This strategic pivot underscores Scinai's commitment to its NanoAb platform, which has the potential to address multiple therapeutic areas. By redirecting resources away from the PC111 program, the company aims to accelerate the development of its most promising assets while strengthening its CDMO operations, which provide a steady revenue stream. The pursuit of grant financing for the psoriasis program and the existing CDMO orders indicate a focus on near-term milestones and financial sustainability.
Investors and industry observers will be watching how Scinai's refocused strategy translates into progress for its NanoAb candidates and growth of its CDMO business. The company's ability to secure the Polish grant and convert committed orders into recognized revenue will be key indicators of its execution. As Scinai streamlines its operations, it positions itself to capitalize on its strengths in immunotherapy innovation and contract manufacturing services.
For more details on Scinai's strategic refocusing, visit the full press release at https://ibn.fm/nnx0Z. For the latest news and updates relating to SCNI, see the company's newsroom at https://ibn.fm/SCNI.
